×
About 3,355 results

ALLMedicine™ Neurofibromatosis Type 1 Center

Research & Reviews  1,279 results

The clinico-pathologic profile of primary and recurrent orbital/periorbital plexiform n...
https://doi.org/10.1371/journal.pone.0258802
PloS One; Alabduljabbar M, Strianese D et. al.

Oct 22nd, 2021 - To evaluate and compare the clinical and histopathological profile of primary and recurrent orbital-periorbital plexiform neurofibromas (OPPN) in patients with neurofibromatosis type 1. We retrospectively evaluated 43 primary or recurrent neurofib...

Impact of systemic anticancer therapy in pediatric optic pathway glioma on visual funct...
https://doi.org/10.1371/journal.pone.0258548
PloS One; Bennebroek CAM, Wijninga LE et. al.

Oct 22nd, 2021 - Pediatric optic pathway glioma (OPG) can seriously decrease visual function in the case of progression. Systemic anticancer therapy (SAT) is considered the treatment of first choice for unresectable OPG. New SAT modalities for the treatment of pro...

PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
https://clinicaltrials.gov/ct2/show/NCT02390752

Oct 21st, 2021 - Background Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventi...

Longitudinal Investigation of Early Motor Development in Neurofibromatosis Type 1.
https://doi.org/10.1093/jpepsy/jsab090
Journal of Pediatric Psychology; Pardej SK, Glad DM et. al.

Oct 20th, 2021 - Research indicates that children with neurofibromatosis type 1 (NF1) have weaknesses in fine and gross motor development in early childhood; however, little is known about the stability and developmental trajectory of motor functioning. We investi...

Endovascular repair for abdominal aortic aneurysm rupture with neurofibromatosis type 1.
https://doi.org/10.1016/j.avsg.2021.07.037
Annals of Vascular Surgery; Nakai S, Uchida T et. al.

Oct 15th, 2021 - Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is a rare congenital disorder with an autosomal dominant inheritance. Severe perioperative complications owing to the congenital fragility of the vascular wall in NF1 patien...

see more →

Guidelines  4 results

Care of adults with neurofibromatosis type 1: a clinical practice resource of the Ameri...
https://doi.org/10.1038/gim.2018.28
Genetics in Medicine : Official Journal of the American C... Stewart DR, Korf BR et. al.

Jul 15th, 2018 - This practice resource is designed primarily as an educational resource for medical geneticists and other clinicians to help them provide quality medical services. Adherence to this practice resource is completely voluntary and does not necessaril...

Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the d...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578356
Neurology Walsh KS, Janusz J et. al.

Aug 17th, 2016 - Neurofibromatosis type 1 (NF1) is associated with neurocognitive deficits that can impact everyday functioning of children, adolescents, and adults with this disease. However, there is little agreement regarding measures to use as cognitive endpoi...

Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomat...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578359
Neurology Ahlawat S, Fayad LM et. al.

Aug 17th, 2016 - The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for assessing disease in patients with ne...

Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578358
Neurology Plotkin SR, Davis SD et. al.

Aug 17th, 2016 - Plexiform neurofibromas (PNs) are complex, benign nerve sheath tumors that occur in approximately 25%-50% of individuals with neurofibromatosis type 1 (NF1). PNs that cause airway compromise or pulmonary dysfunction are uncommon but clinically imp...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  24 results

PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
https://clinicaltrials.gov/ct2/show/NCT02390752

Oct 21st, 2021 - Background Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventi...

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
https://clinicaltrials.gov/ct2/show/NCT02839720

Oct 6th, 2021 - PRIMARY OBJECTIVE: I. Determine if selumetinib sulfate (selumetinib) can result in shrinkage of cutaneous neurofibromas. SECONDARY OBJECTIVE: I. Assess the effect of selumetinib on target inhibition in cutaneous neurofibroma(s) excised prior treat...

Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)
https://clinicaltrials.gov/ct2/show/NCT00111384

Oct 6th, 2021 - We hypothesize that normal germline variation in gene expression accounts, in part, for variation in the clinical severity and phenotype of the monogenic disorder neurofibromatosis type 1 (NF1). The phenotype of NF1 is constituted by a variety of ...

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03739827

Oct 4th, 2021 - Background: Rare tumors are defined as fewer than 150 incident cases per one million per year. Consequently, only 11 tumor types are common in U.S. adults (prostate, breast, lung/bronchus, colon, uterus, bladder, melanoma, rectum, ovary, non-Hodgk...

Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
https://clinicaltrials.gov/ct2/show/NCT04730583

May 27th, 2021 - This study will evaluate the tolerability and effectiveness of four FDA-approved treatments in Neurofibromatosis Type 1 Cutaneous Neurofibromas. These treatments are: a 980nm laser, a 755nm laser, radio-frequency injection, and a Kybella injection...

see more →

News  30 results

Dr. Trent on the Utility of ctDNA to Understand Primary Mutations in GIST
https://www.onclive.com/view/dr-trent-on-the-utility-of-ctdna-to-understand-primary-mutations-in-gist

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD, professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the utility of circulating tumor DNA (ctDNA) to understand primary driver...

Novel Test Distinguishes Benign From Malignant Lesions in NF1
https://www.medscape.com/viewarticle/958224

Sep 6th, 2021 - A novel liquid biopsy test has been shown to distinguish between patients with neurofibromatosis type 1 (NF1) who have benign plexiform neurofibroma (PN) precursor lesions from patients who have malignant peripheral nerve sheath tumors (MPNST), sa...

Neurofibromatosis 1: Making the Diagnosis, With and Without Genetic Testing
https://www.medscape.com/viewarticle/955499

Jul 27th, 2021 - When a child presents with café au lait macules, when is genetic testing for neurofibromatosis type 1 (NF1) advised? According to Peter Kannu, MB, ChB, DCH, PhD, a definitive diagnosis of NF1 can be made in most children using National Institutes ...

Moving Toward Personalized Medicine in Advanced DTC
https://www.onclive.com/view/moving-toward-personalized-medicine-in-advanced-dtc

Apr 2nd, 2021 - Transcript:R. Michael Tuttle, MD: If I can come back to Marcia and Eric to round out this session. I hear you guys talk all the time about doing all this fancy molecular testing, and we test for 400 genes and most of the time it doesn’t help me. I...

2020 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2020-approvals-expand-access-to-care-for-patients-across-tumor-types

Feb 4th, 2021 - In a year marked by collaboration and innovation, therapeutic developments in oncology care once again dominated the novel drug approvals in 2020. In total, 21 novel agents were approved across hematology/ oncology, including 3 diagnostic imaging ...

see more →

Patient Education  4 results see all →